{"id":"docetaxel-only","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Anemia"},{"rate":"20-30%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This prevents cell division and leads to cell death, making it effective in treating various cancers.","oneSentence":"Docetaxel is a microtubule inhibitor that binds to tubulin and prevents microtubule assembly.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:04.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT06223568","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-10","conditions":"Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses","enrollment":70},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT06863272","phase":"PHASE1, PHASE2","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-03","conditions":"Castration-Resistant Prostatic Cancer, Metastasis","enrollment":360},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT04337580","phase":"PHASE2","title":"Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-03-05","conditions":"Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer","enrollment":50},{"nctId":"NCT06952504","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-22","conditions":"Endometrial Cancer","enrollment":1123},{"nctId":"NCT05954312","phase":"PHASE1","title":"A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Vividion Therapeutics, Inc.","startDate":"2023-07-28","conditions":"Advanced Solid Tumors","enrollment":290},{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT05633667","phase":"PHASE2","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-03-16","conditions":"Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer","enrollment":270},{"nctId":"NCT05848011","phase":"PHASE2","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MacroGenics","startDate":"2023-09-28","conditions":"Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent","enrollment":154},{"nctId":"NCT03360890","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2018-03-26","conditions":"Thyroid Cancer, Salivary Gland Cancer","enrollment":46},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT04030455","phase":"PHASE2","title":"Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-08-07","conditions":"Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8","enrollment":28},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT07162051","phase":"PHASE2","title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-03-03","conditions":"HR+/HER2- Early Breast Cancer","enrollment":28},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT02776436","phase":"PHASE1","title":"Reducing Dexamethasone Around Docetaxel Infusion","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2016-01","conditions":"Breast Cancer, Prostate Cancer","enrollment":46},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT03917381","phase":"PHASE1, PHASE2","title":"GEN1046 Safety Trial in Patients With Malignant Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2019-05-14","conditions":"Solid Tumors","enrollment":429},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT04884282","phase":"PHASE2","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2021-10-12","conditions":"Metastatic Non Small Cell Lung Cancer","enrollment":105},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT05616624","phase":"PHASE1, PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-05","conditions":"Non Small Cell Lung Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer","enrollment":31},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT05094336","phase":"PHASE1, PHASE2","title":"A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-02-01","conditions":"Advanced MTAP-null Solid Tumors","enrollment":329},{"nctId":"NCT06123338","phase":"PHASE2","title":"A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation","enrollment":49},{"nctId":"NCT05500092","phase":"PHASE2","title":"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2023-01-25","conditions":"Resectable Stage IIA to IIIB Non-small Cell Lung Cancer","enrollment":17},{"nctId":"NCT07371897","phase":"PHASE3","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-06-30","conditions":"Head and Neck Squamous Cell Carcinoma HNSCC","enrollment":154},{"nctId":"NCT06815497","phase":"PHASE2","title":"Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2026-01-21","conditions":"Ovarian Cancer","enrollment":33},{"nctId":"NCT03246347","phase":"PHASE2","title":"A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-08-23","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":40},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"NSCLC","enrollment":120},{"nctId":"NCT07358806","phase":"PHASE1","title":"Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Oscotec Inc.","startDate":"2025-12-18","conditions":"Solid Tumor, Breast Cancer, Head and Neck Cancer","enrollment":51},{"nctId":"NCT07174388","phase":"","title":"A Study in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"N-Power Medicine","startDate":"2026-01-07","conditions":"Non Small Cell Lung Cancer","enrollment":550},{"nctId":"NCT06967987","phase":"PHASE2","title":"Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b","status":"WITHDRAWN","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2026-01-01","conditions":"Gastric and Gastro-oesophageal Junction (GEJ) Adenocarcinomas, Overexpression FGFR2b","enrollment":""},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT07354984","phase":"PHASE2","title":"A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT06576635","phase":"NA","title":"LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-16","conditions":"NSCLC","enrollment":29},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT03258320","phase":"PHASE2, PHASE3","title":"A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2015-01","conditions":"Prostate Cancer Patients","enrollment":300},{"nctId":"NCT07333066","phase":"PHASE3","title":"Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.","status":"NOT_YET_RECRUITING","sponsor":"Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD","startDate":"2026-03-31","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":320},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":"Carcinoma, Non-Small -Cell Lung","enrollment":300},{"nctId":"NCT07333976","phase":"PHASE2","title":"o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2020-01-05","conditions":"Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neurotoxicity","enrollment":90},{"nctId":"NCT04290793","phase":"PHASE2, PHASE3","title":"Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2020-03-01","conditions":"Breast Cancer","enrollment":113},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT00565851","phase":"PHASE3","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-06","conditions":"Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":1052},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT00781612","phase":"PHASE2","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2008-10-16","conditions":"Neoplasm Metastasis","enrollment":720},{"nctId":"NCT06908993","phase":"PHASE3","title":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-12-09","conditions":"Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation","enrollment":133},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT00309985","phase":"PHASE3","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-09-26","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":790},{"nctId":"NCT03449901","phase":"PHASE2","title":"ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":"Soft Tissue Sarcoma","enrollment":98},{"nctId":"NCT06724042","phase":"PHASE1","title":"Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"InSilico Medicine Hong Kong Limited","startDate":"2026-06-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Advanced and/or Metastatic Solid Tumors","enrollment":159},{"nctId":"NCT03595059","phase":"PHASE1","title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-13","conditions":"Advanced Solid Tumors","enrollment":168},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT07150767","phase":"PHASE1","title":"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","startDate":"2025-03-26","conditions":"Locally Advanced Breast Cancer (LABC)","enrollment":""},{"nctId":"NCT05836584","phase":"PHASE2","title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-06","conditions":"Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8","enrollment":240},{"nctId":"NCT06843681","phase":"PHASE2","title":"Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-03-01","conditions":"Breast Carcinoma in Situ","enrollment":54},{"nctId":"NCT06200558","phase":"","title":"ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2024-01-31","conditions":"Prostate Cancer","enrollment":534},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT06313801","phase":"PHASE2","title":"Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions","status":"RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2023-01-19","conditions":"Gastric Cancer","enrollment":106},{"nctId":"NCT04396535","phase":"PHASE2","title":"Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-10-23","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":10},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT02572843","phase":"PHASE2","title":"Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2016-06-16","conditions":"NSCLC Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03517969","phase":"PHASE2","title":"M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-29","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":73},{"nctId":"NCT03505320","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-29","conditions":"Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer","enrollment":143},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT01382706","phase":"PHASE2","title":"Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2011-06-13","conditions":"Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer","enrollment":15},{"nctId":"NCT05020457","phase":"PHASE2","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-12-07","conditions":"Non Small Cell Lung Cancer","enrollment":69},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT04655976","phase":"PHASE3","title":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2020-12-08","conditions":"Lung Cancer, Non-Small Cell","enrollment":758},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT06682780","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","status":"RECRUITING","sponsor":"LaNova Medicines Limited","startDate":"2025-09-17","conditions":"Advanced Solid Tumor","enrollment":320},{"nctId":"NCT05381038","phase":"PHASE1, PHASE2","title":"Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2023-02-13","conditions":"Solid Tumor, Gastrointestinal Cancer, Breast Cancer","enrollment":10},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT06531434","phase":"PHASE1, PHASE2","title":"Establishing Best Treatment Strategy for T4 Esophageal Cancer","status":"RECRUITING","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-08-01","conditions":"Esophageal Cancer TNM Staging Primary Tumor (T) T4","enrollment":22},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT06874114","phase":"","title":"An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-02-28","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":700},{"nctId":"NCT05076760","phase":"PHASE1","title":"MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Memgen, Inc.","startDate":"2022-04-21","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":40},{"nctId":"NCT07139041","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2025-10","conditions":"NSCLC (Non-small-cell Lung Cancer)","enrollment":69},{"nctId":"NCT06168487","phase":"PHASE1","title":"Telmisartan in Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","startDate":"2024-04-22","conditions":"Prostate Cancer","enrollment":36},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03421288","phase":"PHASE2","title":"Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-09-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":677},{"nctId":"NCT05005728","phase":"PHASE2","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Xencor, Inc.","startDate":"2021-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Docetaxel only","genericName":"Docetaxel only","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel is a microtubule inhibitor that binds to tubulin and prevents microtubule assembly. Used for Breast cancer, Non-small cell lung cancer, Prostate cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}